NasdaqGS - Delayed Quote • USD
PTC Therapeutics, Inc. (PTCT)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 6:44 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 12 | 12 | 13 | 14 |
Avg. Estimate | -1.52 | -1.58 | -5.78 | -4.87 |
Low Estimate | -2.66 | -2.26 | -8.45 | -9.16 |
High Estimate | -0.91 | -1.05 | -2.66 | -1.69 |
Year Ago EPS | -2.66 | -1.76 | -8.37 | -5.78 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 10 | 11 | 13 | 13 |
Avg. Estimate | 148.67M | 142.33M | 606.63M | 621.18M |
Low Estimate | 134.44M | 113.9M | 469.7M | 350M |
High Estimate | 169.37M | 154M | 680.24M | 806.36M |
Year Ago Sales | 213.81M | 196.58M | 937.82M | 606.63M |
Sales Growth (year/est) | -30.50% | -27.60% | -35.30% | 2.40% |
Earnings History
CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
---|---|---|---|---|
EPS Est. | -1.24 | -1.17 | 0.5 | -1.24 |
EPS Actual | -2.66 | -1.76 | -2.06 | -1.2 |
Difference | -1.42 | -0.59 | -2.56 | 0.04 |
Surprise % | -114.50% | -50.40% | -512.00% | 3.20% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -1.52 | -1.58 | -5.78 | -4.87 |
7 Days Ago | -1.53 | -1.59 | -5.84 | -4.99 |
30 Days Ago | -1.54 | -1.6 | -5.88 | -4.98 |
60 Days Ago | -1.72 | -1.72 | -6.23 | -4.99 |
90 Days Ago | -1.64 | -1.62 | -5.79 | -4.48 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 1 | 1 | 2 | 2 |
Up Last 30 Days | 3 | 3 | 4 | 4 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | PTCT | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 42.90% | -- | -- | 5.40% |
Next Qtr. | 10.20% | -- | -- | 10.90% |
Current Year | 30.90% | -- | -- | 4.50% |
Next Year | 15.70% | -- | -- | 13.10% |
Next 5 Years (per annum) | -9.51% | -- | -- | 10.94% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/12/2024 |
Maintains | Jefferies: Buy to Buy | 3/20/2024 |
Reiterates | RBC Capital: Sector Perform to Sector Perform | 3/8/2024 |
Maintains | RBC Capital: Sector Perform to Sector Perform | 3/1/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/1/2024 |
Maintains | TD Cowen: Market Perform to Market Perform | 3/1/2024 |
Related Tickers
CGON CG Oncology, Inc.
41.00
+13.26%
RARE Ultragenyx Pharmaceutical Inc.
44.24
+0.89%
APGE Apogee Therapeutics, Inc.
47.13
+2.77%
INSM Insmed Incorporated
24.80
-0.48%
BPMC Blueprint Medicines Corporation
93.00
+2.50%
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
AGIO Agios Pharmaceuticals, Inc.
31.49
-0.57%
SAGE Sage Therapeutics, Inc.
13.69
+0.81%
MRUS Merus N.V.
45.04
+0.24%
APLS Apellis Pharmaceuticals, Inc.
49.86
+4.03%